Showing results (251-260 of 260) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 260 results.
World Journal of Urology|February 24, 2025
Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impactTatsuo Fukushima, Takuya Tsujino, Moritoshi Sakamoto, et al.
Scientific Reports|July 27, 2025
Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapyTatsushi Kawada, Satoshi Katayama, Takafumi Yanagisawa, et al.
Targeted Oncology|May 28, 2024
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial CarcinomaTaizo Uchimoto, Takuya Matsuda, Kazumasa Komura, et al.
Targeted Oncology|March 28, 2024
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint InhibitorsTaizo Uchimoto, Shuya Tsuchida, Kazumasa Komura, et al.
International Journal of Clinical Oncology|January 31, 2025
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortiumTaizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, et al.
The Prostate|March 31, 2026
A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate CancerKoichiro Kurokawa, Satoshi Yamamoto, Yasutaka Yamada, et al.
Anticancer Research|May 27, 2026
Clinical Features and Prognostic Significance of Pulmonary Metastases in Metastatic Hormone-sensitive Prostate CancerYasutaka Yamada, Marika Matsumoto, Mai Ikehara, et al.
Japanese Journal of Clinical Oncology|May 17, 2025
Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center studyYosuke Kinoshita, Yasutaka Yamada, Takuya Tsujino, et al.
International Journal of Clinical Oncology|October 29, 2024
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan ConsortiumTaizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, et al.
BJU International|November 13, 2025
Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosisTomoki Shirafuji, Yasutaka Yamada, Kodai Sato, et al.
Pageof 26